Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow SPRO
Spero Therapeutics, Inc. (SPRO) EV/Sales
As of 16 October 2026, Spero Therapeutics, Inc. (SPRO) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from −31.1× (February 2018) to 60.5× (April 2018); the current reading is higher than 37% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 2,241.77% |
| FY2024 | 0.1× | 58.52% |
| FY2023 | 0.0× | — |
| FY2022 | −0.8× | — |
| FY2021 | 19.1× | (42.06%) |
| FY2020 | 32.9× | 544.73% |
| FY2019 | 5.1× | — |
| FY2018 | −4.3× | — |
| FY2017 | −28.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.3× | (5.77%) |
| Dec 2025 | 1.4× | (4.20%) |
| Sep 2025 | 1.4× | (47.81%) |
| Jun 2025 | 2.7× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XBIT XBiotech Inc. compare | −8.6× |
| FBIO Fortress Biotech, Inc. compare | −1.4× |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| SPRO Spero Therapeutics, Inc. | 0.2× |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| VRCA Verrica Pharmaceuticals Inc. compare | 2.6× |
| HYFT MindWalk Holdings Corp. compare | 5.1× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)